Personalized treatment with bacteria-infecting viruses, called bacteriophages, could be used to combat Pseudomonas aeruginosa, the main bacteria involved in…
Articles by Marisa Wexler, MS
Treatment with Trikafta may improve nutritional status or lessen anemia among some people with cystic fibrosis (CF) who…
Treatment with Trikafta lowered the need for antibiotics and mucus-clearing therapies among children…
Treatment with Trikafta rapidly eases symptoms of chronic nose and sinus inflammation in…
Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment…
Clinicians who are caring for people with cystic fibrosis (CF) should talk to their patients about pregnancy and family…
Six months of treatment with Trikafta does not substantially alter digestive symptoms in people with cystic fibrosis (CF), new…
For children with cystic fibrosis (CF), newborn screening is associated with markedly improved real-world outcomes, including earlier…
People with cystic fibrosis (CF) who start on the triple therapy Trikafta may be at greater risk of…
Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis…